Cellular basis of uraemic cardiomyopathy: A role for erythropoietin?

European Journal of Heart Failure

Volumn 11, Issue 8, 2009, Pages 732-738

  Smith, Katie ^a   Semple, David ^a   Bhandari, Sunil ^b   Seymour, Anne Marie L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Erythropoietin; Left ventricular hypertrophy; Remodelling; Uraemic cardiomyopathy

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NITRIC OXIDE;

ANEMIA; ANGIOGENESIS; APOPTOSIS; CARDIOMYOPATHY; CELL PROTECTION; CHRONIC KIDNEY DISEASE; ERYTHROPOIESIS; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEMATOPOIESIS; HUMAN; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UREMIA; BIOSYNTHESIS; CYTOLOGY; FIBROSIS; HEART MUSCLE; HEART VENTRICLE REMODELING; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

CARDIOMYOPATHIES; ERYTHROPOIETIN; FIBROSIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; RECEPTORS, ERYTHROPOIETIN; RISK FACTORS; SIGNAL TRANSDUCTION; UREMIA; VENTRICULAR REMODELING;

EID: 67749127495     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp093     Document Type: Review

References (105)

1. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z et al Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-7584.
2. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006;71:684-694.
3. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-133.
4. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ, Schoemaker RG, van Gilst WH. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing hae-matocrit. Eur J Heart Fail 2008;10:22-29.
5. Causes of death. United States Renal Data System. Am J Kidney Dis 1998; 32(Suppl. 2 1):S81-S88.
6. Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G et al Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992;7(Suppl. 2):7-35.
7. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(Suppl. 3):S112-S119.
8. Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. Kidney Int 2003; 63:1462-1467.
9. Aksentijevic D, Bhandari S, Seymour A-ML. Insulin resistance and altered GLUT4 expression in experimental uremia. Kidney Int 2009;75:711- 718.
10. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
11. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290.
12. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34: 125-134.
13. Ritz E, McClellan WM. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 2004;15:513-516.
14. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759-2767.
15. Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med 1980;69:576-584.
16. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-864.
17. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation1990;81:815-820.
18. Meerson FZ. Mechanism of hypertrophy of the heart and experimental prevention of acute cardiac insufficiency. Br Heart J 1971;33(suppl.):100-108.
19. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996;49: 1428-1434.
20. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 1994;267:H742-H750.
21. Nascimben L, Ingwall JS, Lorell BH, Pinz I, Schultz V, Tornheim K, Tian R. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 2004; 44:662-667.
22. Akki A, Smith K, Seymour AM. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem2008;311:215-224.
23. Seymour AM. Mitochondrial function - a limiting factor in heart failure?Dhalla NS, Angel A, Pierce GN, eds. Pathophysiology of Cardiovascular Disease. Boston: Kluwer Academic Publishers; 2003.
24. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of per-oxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000;105:1723-1730.
25. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 2002;7:175-185.
26. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA1999;96:7473-7478.
27. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007;356: 1140-1151.
28. Russell RR III, Taegtmeyer H. Coenzyme A sequestration in rat hearts oxidizing ketone bodies. J Clin Invest 1992;89:968-973.
29. Seymour AM, Chatham JC. The effects of hypertrophy and diabetes on cardiac pyruvate dehydrogenase activity. J Mol Cell Cardiol 1997;29:2771-2778.
30. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:1018-1022.
31. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int 1992;42:1079-1085.
32. Amann K, Neimeier KA, Schwarz U, Tornig J, Matthias S, Orth SR, Mall G, Ritz E. Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle. Am J Kidney Dis 1997;30:382-388.
33. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 2004;15:1530-1536.
34. Seymour AM. Imaging cardiac metabolism in heart failure: the potential of NMR spectroscopy in the era of metabolism revisited. Heart Lung Circ 2003;12:25-30.
35. Borutaite V, Brown GC. Mitochondria in apoptosis of ischemic heart. FEBS Lett 2003;541:1-5.
36. Amann K, Ritz E. Reduced cardiac ischaemia tolerance in uraemia - what is the role of structural abnormalities of the heart? Nephrol Dial Transplant 1996;11: 1238-1241.
37. Kalk P, Eggert B, Relle K, Godes M, Heiden S, Sharkovska Y, Fischer Y, Ziegler D, Bielenberg GW, Hocher B. The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol 2007;151:1025-1032.
38. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E. Myocardial interstitial fibrosis in experimental uremia - implications for cardiac compliance. Kidney Int 1988;33:804-811.
39. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990;5:39-44.
40. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 1997;4:212-224.
41. Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4: 1814-1819.
42. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K, Ehmke H, Mall G, Ritz E. Cardiac remodelling in experimental renal failure - an immunohis-tochemical study. Nephrol Dial Transplant1998;13:1958- 1966.
43. Saito T, Tamura K, Uchida D, Saito T, Togashi M, Nitta T, Sugisaki Y. Histopathological features of the resected left atrial appendage as predictors of recurrence after surgery for atrial fibrillation in valvular heart disease. Circ J2007;71:70-78.
44. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 2001;88:275-279.
45. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002;137: 555-562.
46. Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979;93:449- 458.
47. Eschbach JW, Varma A, Stivelman JC. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? Nephrol Dial Transplant 2002;17(Suppl. 5):2-7.
48. Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, Caramelo C. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998;54:1337-1343.
49. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-95.
50. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1-14.
51. Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P. Peritubular cells are the site of ery-thropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988;81: 620-623.
52. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538-548.
53. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993;74:227-236.
54. Sawyer ST, Penta K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem1996;271:32430-32437.
55. Um M, Lodish HF. Antiapoptotic effects of erythropoietin in differentiated neu-roblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem2006;281:5648-5656.
56. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, Fernandez-Luna JL. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999;274: 22165-22169.
57. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a - / - 5b - / - mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999;98:181-191.
58. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005;19:1323-1325.
59. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of ery-thropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
60. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999;253:143-156.
61. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412: 641-647.
62. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526- 10531.
63. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M, Rosenbaum DM. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002;99:10659-10664.
64. Ammarguellat F, Gogusev J, Drueke TB. Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 1996;11:687-692.
65. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-3978.
66. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-14912.
67. Depping R, Kawakami K, Ocker H, Wagner JM, Heringlake M, Noetzold A, Sievers HH, Wagner KF. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 2005;130:877-878.
68. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J2004;25:285- 291.
69. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004;18:1031-1033.
70. Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, Mackenzie ET, Petit E. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000;30:271-278.
71. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med2002;8:495-505.
72. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA2003;100:11612-11617.
73. Shi Y, Rafiee P, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 2004;99:173-182.
74. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-4806.
75. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308:990-994.
76. Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther2005;19:333-336. Sponsored by the International Society of Cardiovascular Pharmacotherapy.
77. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005;102: 2046-2051.
78. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, Talan MI. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006; 316:999-1005.
79. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, Matsunaga S, Tateishi K, Nomura T, Takahashi T, Tatsumi T, Matsubara H. Erythropoietinmobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyper-plasia. Circ Res 2006;98:1405-1413.
80. d'Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 2007;49:1142-1148.
81. Piuhola J, Kerkela R, Keenan JI, Hampton MB, Richards AM, Pemberton CJ. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin Sci 2008;114:293-304.
82. Shan X, Xu X, Cao B, Wang Y, Guo L, Zhu Q, Li J, Que L, Chen Q, Ha T, Li C, Li Y. Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury. Int J Cardiol 2008;134: 384-392.
83. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 2007;116:173-191.
84. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfu-sion injury. Circulation 2004;109:2050-2053.
85. Sivertsen EA, Hystad ME, Gutzkow KB, Dosen G, Smeland EB, Blomhoff HK, Myklebust JH. PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells. Br J Haematol 2006;135:117-128.
86. Ohori K, Miura T, Tanno M, Miki T, Sato T, Ishikawa S, Horio Y, Shimamoto K. Ser9 phosphorylation of mitochondrial GSK-3{beta} is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol 2008;295:H2079-H2086.
87. Kim MY, Kim MJ, Yoon IS, Ahn JH, Lee SH, Baik EJ, Moon CH, Jung YS. Diazoxide acts more as a PKC-epsilon activator, and indirectly activates the mitochondrial K(ATP) channel conferring cardioprotection against hypoxic injury. Br J Pharmacol 2006;149:1059-1070.
88. Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005;100:187-197.
89. Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 2005;106: 147-162.
90. Smith RS Jr, Agata J, Xia CF, Chao L, Chao J. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxi-dative stress after myocardial infarction. Life Sci 2005;76:2457-2471.
91. Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 2006;72:51-59.
92. Joyeux-Faure M, Ramond A, Beguin PC, Belaidi E, Godin-Ribuot D, Ribuot C. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam Clin Pharmacol 2006;20:51-56.
93. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, Abel ED, Xenocostas A, Kvietys PR. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 2005;65:719-727.
94. Seddon M, Shah AM, Casadei B. Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc Res 2007;75:315-326.
95. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694- 2701.
96. Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006;101:31-39.
97. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovasculariza-tion. Eur Heart J2007;28:2018-2027.
98. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res2002;64: 326-333.
99. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 2005;68:299-306.
100. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990;6:1-4.
101. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35: 250-256.
102. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med2006;355:2071-2084.
103. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
104. van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail2007;9:110-112.
105. Reddy V, Bhandari S, Seymour A-M. Myocardial function, energy provision and carnitine deficiency in experimental uremia. J Am Soc Nephrol 2007;18:84-92.